An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10mg) in Japanese Patients With Type 2 Diabetes
Phase 1
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-jRCT2080221000
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Already on voglibose treatment with a steady dosage for at least 8 weeks
- Provision of informed consent prior to any study specific procedures
- Diagnosed with type 2 diabetes
Exclusion Criteria
- Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease.
- The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method